Advancing Lung Cancer Treatment with Combined c-Met Promoter-Driven Oncolytic Adenovirus and Rapamycin

Area of Science:

• Oncolytic virotherapy
• Molecular oncology
• Cancer therapeutics

Background:

• Lung cancer, particularly non-small cell lung cancer (NSCLC), presents significant mortality and morbidity challenges.
• Overexpressed or mutated receptor tyrosine kinases, like c-Met, drive lung cancer progression, including growth, invasion, and metastasis.
• Oncolytic adenoviruses show enhanced antitumor efficacy when combined with chemotherapy.

Purpose of the Study:

• To investigate the efficacy of a novel oncolytic adenovirus (Ad.What) driven by the c-Met promoter for targeting lung cancer.
• To evaluate the synergistic effects of combining Ad.What with rapamycin, a selective mTOR inhibitor, for lung cancer treatment.

Main Methods:

• Development of a replication-selective oncolytic adenovirus (Ad.What) regulated by the c-Met promoter to target lung cancer cells.
• Combination therapy of Ad.What with rapamycin to assess its impact on cancer cell infectivity and antitumor activity.
• Analysis of coxsackievirus and adenovirus receptor (CAR) and αV integrin expression, and induction of autophagy in cancer cells.

Main Results:

• The Ad.What adenovirus effectively targeted lung cancer cells overexpressing c-Met, sparing normal cells.
• Combination with rapamycin significantly increased cancer cell infectivity by upregulating CAR and αV integrin expression.
• The combination therapy also successfully induced autophagy in cancer cells.

Conclusions:

• A c-Met promoter-driven oncolytic adenovirus combined with rapamycin represents a potentially effective strategy for treating lung cancer.
• This targeted approach exploits specific vulnerabilities in lung cancer cells, offering a promising advancement in cancer therapy.
• The combination enhances viral entry and induces autophagy, suggesting a multi-pronged attack against the disease.